BioVeda Capital

The firm invests across Asia, with a primary focus on Southeast Asia, India, and North Asian markets. Its Singapore headquarters provides proximity to regional regulatory bodies, clinical-trial infrastructure, and the Biopolis biomedical research cluster. No additional offices beyond Singapore are publicly documented.

BioVeda operates through direct equity investments in healthcare companies rather than acting as a fund-of-funds allocator. The firm takes structured minority positions and participates in venture and growth-stage rounds. Fund structure details — whether the firm raises discretionary funds or deploys on a deal-by-deal basis — are not available in public disclosures.

BioVeda has not publicly disclosed the identities of its managing principals, investment committee members, or portfolio managers. No named executives appear in press coverage, regulatory filings, or the firm's limited digital footprint as of mid-2026. The absence of disclosed leadership is notable for an institutional allocator conducting operational due diligence.